期刊文献+

卞丝肼对6-OHDA损毁大鼠纹状体细胞外多巴胺水平的影响 被引量:1

Effects of benserazide on extracellular dopamine level in striatum of 6-hydroxydopamine-lesioned rats
下载PDF
导出
摘要 目的:观察卞丝肼对6-羟多巴胺(6-OHDA)所致帕金森病模型大鼠纹状体细胞外多巴胺(DA)水平的影响。方法:采用6-OHDA建立帕金森病大鼠模型(黑质纹状体去神经支配),用生理盐水制作假损毁大鼠作为对照;而后采用卞丝肼和卞丝肼联合L-多巴胺(L-DOPA)治疗,应用体内微渗析技术分别检测假损毁和6-OHDA损毁大鼠纹状体细胞外DA水平。结果:在假损毁大鼠中,50mg·kg-1卞丝肼可以使细胞外DA水平明显降低(P<0.01)。在6-OHDA损毁大鼠纹状体中,卞丝肼和L-DOPA的共同用药使细胞外DA水平明显升高,但是达到峰值的时间明显延长,并呈现剂量依赖性(P<0.05)。结论:卞丝肼可降低黑质丝状体去神经支配大鼠丝状体氨基酸脱羧酶(AADC)活性,改变外来性L-DOPA的代谢。较高剂量卞丝肼可能会阻止L-DOPA长期治疗所导致的不良反应。 Objective To study the effects of benserazide on extracellular dopamine level in the striatum of 6-hydroxydopamine-lesioned Parkinson's disease rat models.Methods The rat models of nigrostriatal denervation of Parkinson's disease were set up by using 6-hydroxydopamine(6-OHDA),and the control rats were treated with isotonic Na chloride.Then the extracellular dopamine(DA)level in the striatum of sham-lesioned rats treated with benserazide alone and in the striatum of 6-OHDA-lesioned rats treated with benserazide in combination with L-DOPA were detected by using in vivo microdialysis technique.Results In sham-lesioned rats,the extracellular DA level was significantly decreased by 50 mg·kg-1benserazide(P〈0.01).In 6-OHDA-lesioned rats,the extracellular DA level showed a marked increase by the combined use of benserazide and L-DOPA,but the time to reach the peak level was significantly prolonged on a dose-dependent manner(P〈0.05).Conclusion Benserazide can reduce the central AADC activity in the striatum of rats with nigrostriatal denervation,resulting in changes in metabolism of exogenous L-DOPA.And higher dose of benserazide might be a useful agent to prevent adverse effects of long-term L-DOPA therapy.
出处 《吉林大学学报(医学版)》 CAS CSCD 北大核心 2010年第4期660-663,共4页 Journal of Jilin University:Medicine Edition
基金 吉林省科技厅杰出青年科学研究计划项目资助课题(20070132)
关键词 卞丝肼 多巴胺 动物模型 微渗析技术 芳香氨基酸脱羧酶 benserazide L-DOPA dopamine animal model microdialysis aromatic L-amino acid decarboxylase
  • 相关文献

参考文献8

  • 1Hornykiewicz O, Kish SJ. Biochemical pathophysiology of Parkinson' s disease [J]. Adv Neurol, 1987, 45 (1): 19-34.
  • 2Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism [J]. N Engl J Med, 1967, 276 (7): 374-379.
  • 3Rinne UK, Birket-Smith E, Dupont E, et al. Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (Madopar) in the treatment of Parkinson's disease: A controlled clinical trial [J]. J Neurol, 1975, 211 (1): 1-9.
  • 4Munoz-Munoz JL, Garcia-Molina F, Garcia-Molina M, et al. Kinetic characterization of the oxidation of carbidopa and benserazide by tyrosinase and peroxidase [J]. Biosci Biotechnol Biochem, 2009, 73 (6) : 1308-1313.
  • 5Pani L, Gessa GL, Carboni S, et al. Brain dialysis and dopamine: does the extracellular concentration of dopamine reflect synaptic release? [J]. Eur J Pharmacol, 1990, 180 (1): 85-90.
  • 6Yokochi M, Kondo T, Hirayama K, et al. Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, benserazide-HC1, on Parkinson' s disease - Part Ⅱ: Pharmacokinetic study (author's transl)[J]. No To Shinkei, 1979, 31(4): 339- 348.
  • 7Pezzoli G, Zini M. Levodopa in Parkinson' s disease: from the past to the future [J]. Expert Opin Pharmacother, 2010, 11 (4): 627-635.
  • 8BlechingbergJ, Holm IE, Johansen MG, et al. Aromatic I amino acid decarboxylase expression profiling and isoform detection in the developing porcine brain [J]. Brain Res, 2010, 1308: 1-13.

同被引文献7

  • 1COTZIAS G C,VAN WOERT M H,SCHIFFER L M. Aromatic amino acids and modification of parkinsonism[J].New England Journal of Medicine,1967,(07):374-379.
  • 2TRESEDER S A,ROSE S,SUMMO L. Commonly used L-amino acid decarboxylase inhibitors block monoamine oxidase activity in the rat[J].Journal of Neural Transmission,2003.229-238.
  • 3TRESEDER S A,ROSE S,JENNER P. The central aromatic amino acid DOPA decarboxylase inhibitor,NSD-1015,does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned rats[J].European Journal of Neuroscience,2001.162-170.
  • 4TRESEDER S A,ROSE S,JENNER P. The central DOPA decarboxylase inhibitor,NSD-1015,does not prevent L-DOPA-induced circling behaviour in 60HDA-lesioned rats[J].British Journal of Pharmacology,1999,(SS):24.
  • 5ZHAO H,NEAMATI N,SUNDER S. Hydrazide-containing inhibitors of HIV-1 integrase[J].Journal of Medicinal Chemistry,1997.937-941.
  • 6DRAIN D J,WILLIAMS H W R. Substituted benzyl hydrazines and semicarbazides and processes for marking them[P].United Kingdom,GB924600,1961.
  • 7XU Z M,SINGH J,SCHWINDEN M D. Process research and development for an efficient synthesis of the HIV protease inhibitor BMS-232632[J].Organic Process Research & Development,2002.323-328.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部